medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2019-2-30(405)-12-17medalphabet-1114Research ArticleСтатьиСовременные подходы к ведению пациентов с фибрилляцией предсердий и чрескожным коронарным вмешательствомCurrent management approaches to patients with atrial fibrillation and percutaneous coronary interventionБарбарашО. Л.BarbarashO. L.

д. м. н., проф., член-корр. РАН, директор НИИ КПССЗ; зав. кафедрой кардиологии и сердечно-сосудистой хирургии КемГМУ

г. Кемерово

Kemerovo

КашталапВ. В.KashtalapV. V.

д. м. н., доцент, зав. лабораторией патофизиологии мультифокального атеросклероза НИИ КПССЗ; доцент кафедры кардиологии и сердечно-сосудистой хирургии КемГМУ

г. Кемерово

Kemerovo

ФГБНУ «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний»; ФГБОУ ВО «Кемеровский государственный медицинский университет» Минздрава РоссииРоссияResearch Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical UniversityRussian Federation201916112019230Артериальная гипертензия и коморбидность1217Copyright © Барбараш О.Л., Кашталап В.В., 20192019Барбараш О.Л., Кашталап В.В.Barbarash O.L., Kashtalap V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/1114

В обзорной статье представлены актуальные позиции американских и европейских клинических рекомендаций в отношении антитромботической терапии у сложной категории пациентов —  больных с сочетанием фибрилляции предсердий и ишемической болезни сердца, которым выполняется чрескожное коронарное вмешательство. Отмечены сходства и различия позиций двух экспертных сообществ, а также существующая в настоящее время доказательная база в отношении выбора оптимальной схемы антитромботической терапии. Обозначены преимущественные позиции клопидогрела при выборе дезагреганта для двойной или тройной антитромботической терапии.

In this review are provided relevant positions of the American and European clinical guidelines for antithrombotic therapy in the patients with a combination of atrial fibrillation and coronary heart disease with percutaneous coronary intervention. Similarities and distinctions of positions of two expert communities were discussed. In addition, the evidence-based positions concerning the choice of the optimal antithrombotic therapy are noted. Primary positions of a clopidogrel when choosing the antiagregants for double or triple antithrombotic therapy were designated.

фибрилляция предсердийчрескожные коронарные вмешательстваантиагрегантыантикоагулянтыatrial fibrillationcoronary heart diseaseanticoagulantsclopidogrelReferencesPiepoli Mf, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The sixth Joint Task force of the European society of Cardiology and Other societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & rehabilitation (eACPr). Eur Heart J, 2016; 37 (29): 2315–2381.Piepoli Mf, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The sixth Joint Task force of the European society of Cardiology and Other societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & rehabilitation (eACPr). Eur Heart J, 2016; 37 (29): 2315–2381.Michniewicz E, Mlodawska E, Lopatowska P, Tomaszuk-Kazberuk A, Malyszko J. Patients with atrial fibrillation and coronary artery disease–double trouble. Adv Med Sci 2018; 63: 30–35.Michniewicz E, Mlodawska E, Lopatowska P, Tomaszuk-Kazberuk A, Malyszko J. Patients with atrial fibrillation and coronary artery disease–double trouble. Adv Med Sci 2018; 63: 30–35.Capodanno D, Huber K, Mehran R, Lip GYH, Faxon DP, Granger CB, Vranckx P, Lopes RD, Montalescot G, Cannon CP, Ten Berg J, Gersh BJ, Bhatt DL, Angiolillo DJ. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Jul 9; 74(1): 83–99. DOI: 10.1016/j.jacc.2019.05.016.Capodanno D, Huber K, Mehran R, Lip GYH, Faxon DP, Granger CB, Vranckx P, Lopes RD, Montalescot G, Cannon CP, Ten Berg J, Gersh BJ, Bhatt DL, Angiolillo DJ. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Jul 9; 74(1): 83–99. DOI: 10.1016/j.jacc.2019.05.016.Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018; 39: 213–260.Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018; 39: 213–260.Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39: 1330–1393.Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39: 1330–1393.Huisman MV, et al. The Changing Landscape for stroke Prevention in Af: findings from the GLORIA-AF registry Phase 2. J Am Coll Cardiol, 2017; 69 (7): 777–785.Huisman MV, et al. The Changing Landscape for stroke Prevention in Af: findings from the GLORIA-AF registry Phase 2. J Am Coll Cardiol, 2017; 69 (7): 777–785.Польшакова И. Л., Поветкин С. В. Структура лекарственной терапии и клиническая характеристика больных с фибрилляцией предсердий по данным исследования РЕКУР-ФП. Рациональная фармакотерапия в кардиологии. 2018; 14 (5): 733–740. doi.org/10.20996/1819–6446–2018–14–5–733–740.Polshakova I. L., Povetkin S. V. Drug Therapy Structure and Clinical Characteristics of Patients with Atrial Fibrillation According to Data of REKUR-AF Study. Rational Pharmacotherapy in Cardiology. 2018; 14 (5): 733–740. (In Russ.) doi.org/10.20996/1819–6446–2018–14–5–733–740.Алекян Б. Г., Карапетян Н. Г. Современные российские тенденции рентгенэндоваскулярного и хирургического лечения некоторых изолированных пороков сердца. Эндоваскулярная хирургия. 2019; 6 (2): 98–106. DOI: 10.24183/2409–4080–2019–6–2–98–106.Alekyan B. G., Karapetyan N. G. Modern Russian trends in endovascular and surgical treatment of some isolated heart diseases. Russian Journal of Endovascular Surgery. 6 (2); 98–106. (in Russian). DOI: 10.24183/2409–4080–2019–6–2–98–106.Бокерия Л. А., Милиевская Е. Б., Кудзова З. Ф., Прянишников В. В. Сердечно-сосудистая хирургия — 2017. Болезни и врожденные аномалии системы кровообращения. М.: НМИЦССХ им А. Н. Бакулева МЗ РФ; 2018. — 252 c.Bokeriya L. A., Milievskaya E. B., Kudzova Z. F., Spinnishnikov V. V. Cardiovascular surgery — 2017. Diseases and congenital abnormalities of the circulatory system. Moscow: NMITSSH named after A. N. Bakulev of the Ministry of Healthcare of the Russian Federation; 2018. — 252 p. (in Russian).Lip GYH, Collet J-P, Haude M, et al. 2018 joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace. 2019; 21: 192–193.Lip GYH, Collet J-P, Haude M, et al. 2018 joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace. 2019; 21: 192–193.Shanmugasundaram M, Hashemzadeh M, Movahed M. Outcomes of percutaneous coronary intervention in patients with atrial fibrillation. JACC March 20, 2018; 71 (11): 1024.Shanmugasundaram M, Hashemzadeh M, Movahed M. Outcomes of percutaneous coronary intervention in patients with atrial fibrillation. JACC March 20, 2018; 71 (11): 1024.Loukianov M. M., Boytsov S. A., Yakushin S. S., Martsevich S. Y., Vorobyev A. N., Zagrebelnyy A. V., Kharlap M. S., Pereverzeva K. G., Pravkina E. A., Serdyuk S. E., Deev A. D., Kudryashov E. N. Diagnostics, treatment, associated cardiovascular and concomitant non-cardiac diseases in patients with diagnosis of “atrial fibrillation” in real outpatient practice (according to data of registry of cardiovascular diseases, RECVASA). Rational Pharmacotherapy in Cardiology. 2014; 10 (4): 366–377 (in Russ.). doi.org/10.20996/1819–6446–2014–10–4–366–377.Loukianov M. M., Boytsov S. A., Yakushin S. S., Martsevich S. Y., Vorobyev A. N., Zagrebelnyy A. V., Kharlap M. S., Pereverzeva K. G., Pravkina E. A., Serdyuk S. E., Deev A. D., Kudryashov E. N. Diagnostics, treatment, associated cardiovascular and concomitant non-cardiac diseases in patients with diagnosis of “atrial fibrillation” in real outpatient practice (according to data of registry of cardiovascular diseases, RECVASA). Rational Pharmacotherapy in Cardiology. 2014; 10 (4): 366–377 (in Russ.). doi.org/10.20996/1819–6446–2014–10–4–366–377.Кашталап В. В., Барбараш О. Л. Актуальные проблемы антитромботической терапии при остром коронарном синдроме (по материалам Европейского конгресса кардиологов 2017). Медицинский совет. 2017; 12: 82–88. 10.21518/2079–701X-2017–12–82–88.Kashtalap VV, Barbarash OL. Actual problems of antithrombotic therapy in acute coronary syndrome (following the material presented at the European society of cardiology congress 2017). Medical Council. 2017; 12: 82–88 (in Russian). 10.21518/2079–701X-2017–12–82–88.Connolly S, Pogue J, Hart R, et al., for the ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903–1912.Connolly S, Pogue J, Hart R, et al., for the ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903–1912.Connolly SJ, Pogue J, Hart RG, et al., for the ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360: 2066–2078.Connolly SJ, Pogue J, Hart RG, et al., for the ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360: 2066–2078.Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806–817.Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806–817.Simmers MB, Cole BK, Ogletree ML, et al. Hemodynamics associated with atrial fibrillation directly alters thrombotic potential of endothelial cells. Thromb Res 2016; 143: 34–39.Simmers MB, Cole BK, Ogletree ML, et al. Hemodynamics associated with atrial fibrillation directly alters thrombotic potential of endothelial cells. Thromb Res 2016; 143: 34–39.van Rein N, Heide-Jørgensen U, Lijfering WM, Dekkers OM, Sørensen HT, Cannegieter SC. Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy. Circulation 2019; 139: 775–786.van Rein N, Heide-Jørgensen U, Lijfering WM, Dekkers OM, Sørensen HT, Cannegieter SC. Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy. Circulation 2019; 139: 775–786.January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW.2019 AHA/ACC/ HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Writing Group Members, Heart Rhythm. 2019 Aug; 16 (8): e66-e93. DOI: 10.1016/j.hrthm.January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW.2019 AHA/ACC/ HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Writing Group Members, Heart Rhythm. 2019 Aug; 16 (8): e66-e93. DOI: 10.1016/j.hrthm.Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; 2018 ESC/EACTS Guidelines on myocardial revascularization. ESC Scientific Document Group. Eur Heart J. 2019 Jan 7; 40 (2): 87–165. DOI: 10.1093/eurheartj/ehy394.Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; 2018 ESC/EACTS Guidelines on myocardial revascularization. ESC Scientific Document Group. Eur Heart J. 2019 Jan 7; 40 (2): 87–165. DOI: 10.1093/eurheartj/ehy394.Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016; 18: 1609–1678.Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016; 18: 1609–1678.Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet 2014; 383: 955–962.Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet 2014; 383: 955–962.Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375: 2423–2434.Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375: 2423–2434.Cannon CP, Bhatt DL, Oldgren J, et al. Dual Antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017; 377: 1513–1524.Cannon CP, Bhatt DL, Oldgren J, et al. Dual Antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017; 377: 1513–1524.Chi G, Kerneis M, Kalayci A, et al. Safety and efficacy of non–vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: a bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial. Am Heart J 2018; 203: 17–24.Chi G, Kerneis M, Kalayci A, et al. Safety and efficacy of non–vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: a bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial. Am Heart J 2018; 203: 17–24.Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019; 380: 1509–1524.Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019; 380: 1509–1524.Rossini R, Musumeci G, Lettieri C, et al. Longterm outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol 2008; 102: 1618–1623.Rossini R, Musumeci G, Lettieri C, et al. Longterm outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol 2008; 102: 1618–1623.Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381: 1107–1115.Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381: 1107–1115.Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation. J Am Coll Cardiol 2015; 65: 1619–1629.Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation. J Am Coll Cardiol 2015; 65: 1619–1629.Schömig A, Neumann F-J, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084–1089.Schömig A, Neumann F-J, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084–1089.Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998; 98: 1597–1603.Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998; 98: 1597–1603.Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998; 98: 2126–2132.Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998; 98: 2126–2132.Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998; 339: 1665–1671.Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998; 339: 1665–1671.Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel. J Am Coll Cardiol 2007; 49: 1505–1516.Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel. J Am Coll Cardiol 2007; 49: 1505–1516.CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–1339.CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–1339.Bhatt DL, Hirsch AT, Ringleb PA, Hacke W, Topol EJ, for the CAPRIE Investigators. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. Am Heart J 2000; 140: 67–73.Bhatt DL, Hirsch AT, Ringleb PA, Hacke W, Topol EJ, for the CAPRIE Investigators. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. Am Heart J 2000; 140: 67–73.Storey RF. Biology and pharmacology of the platelet P2Y 12 receptor. Curr Pharm Des 2006; 12: 1255–1259.Storey RF. Biology and pharmacology of the platelet P2Y 12 receptor. Curr Pharm Des 2006; 12: 1255–1259.Perzborn E, Heitmeier S, Laux V. Effects of rivaroxaban on platelet activation and plateletcoagulation pathway interaction: in vitro and in vivo studies. J Cardiovasc Pharmacol Ther 2015; 20: 554–562.Perzborn E, Heitmeier S, Laux V. Effects of rivaroxaban on platelet activation and plateletcoagulation pathway interaction: in vitro and in vivo studies. J Cardiovasc Pharmacol Ther 2015; 20: 554–562.Angiolillo DJ, Goodman SG, Bhatt DL, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective-2018 update. Circulation 2018; 138: 527–536.Angiolillo DJ, Goodman SG, Bhatt DL, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective-2018 update. Circulation 2018; 138: 527–536.Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ. Dual antiplatelet therapy: appraisal of the ACC/AHA and ESC focused updates. J Am. Coll Cardiol 2018; 72: 103–119.Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ. Dual antiplatelet therapy: appraisal of the ACC/AHA and ESC focused updates. J Am. Coll Cardiol 2018; 72: 103–119.Sarafoff N, Martischnig A, Wealer J, et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol 2013; 61: 2060–2066.Sarafoff N, Martischnig A, Wealer J, et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol 2013; 61: 2060–2066.Angiolillo DJ, Rollini F, Storey RF, et al. International expert consensus on switching platelet P2Y 12 receptor–inhibiting therapies. Circulation 2017; 136: 1955–1975.Angiolillo DJ, Rollini F, Storey RF, et al. International expert consensus on switching platelet P2Y 12 receptor–inhibiting therapies. Circulation 2017; 136: 1955–1975.Hamon M, Lemesle G, Tricot O, et al. Incidence, source, determinants, and prognostic impact of major bleeding in outpatients with stable coronary artery disease. J Am Coll Cardiol 2014; 64: 1430–1436.Hamon M, Lemesle G, Tricot O, et al. Incidence, source, determinants, and prognostic impact of major bleeding in outpatients with stable coronary artery disease. J Am Coll Cardiol 2014; 64: 1430–1436.Alexander JH, Lopes RD, Thomas L, et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2014; 35: 224–232.Alexander JH, Lopes RD, Thomas L, et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2014; 35: 224–232.

The authors declare that there are no conflicts of interest present.